Complement-Coagulation Cross-Talk: A Potential Mediator of the Physiological Activation of Complement by Low pH by Hany Ibrahim Kenawy et al.
REVIEW
published: 06 May 2015
doi: 10.3389/fimmu.2015.00215
Edited by:
Timothy B. Niewold,
Mayo Clinic, USA
Reviewed by:
Francesco Tedesco,
University of Trieste, Italy
Viviana P. Ferreira,
University of Toledo, USA
*Correspondence:
Hany Ibrahim Kenawy,
Microbiology and Immunology
Department, Faculty of Pharmacy,
Mansoura University, Mansoura
35516, Egypt
hany.kenawy@googlemail.com
Specialty section:
This article was submitted to
Molecular Innate Immunity, a section
of the journal Frontiers in Immunology
Received: 25 January 2015
Paper pending published:
16 March 2015
Accepted: 18 April 2015
Published: 06 May 2015
Citation:
Kenawy HI, Boral I and Bevington A
(2015) Complement-coagulation
cross-talk: a potential mediator of the
physiological activation of
complement by low pH.
Front. Immunol. 6:215.
doi: 10.3389/fimmu.2015.00215
Complement-coagulation cross-talk:
a potential mediator of the
physiological activation of
complement by low pH
Hany Ibrahim Kenawy 1*, Ismet Boral 2 and Alan Bevington 2
1 Department of Microbiology and Immunology, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt, 2 Department of
Infection, Immunity and Inflammation, College of Medicine, Biological Sciences and Psychology, University of Leicester,
Leicester, UK
The complement system is a major constituent of the innate immune system. It not
only bridges innate and adaptive arms of the immune system but also links the immune
system with the coagulation system. Current understanding of the role of complement
has extended far beyond fighting of infections, and now encompasses maintenance
of homeostasis, tissue regeneration, and pathophysiology of multiple diseases. It has
been known for many years that complement activation is strongly pH sensitive, but
only relatively recently has the physiological significance of this been appreciated. Most
complement assays are carried out at the physiological pH 7.4. However, pH in some
extracellular compartments, for example, renal tubular fluid in parts of the tubule, and
extracellular fluid at inflammation loci, is sufficiently acidic to activate complement. The
exact molecular mechanism of this activation is still unclear, but possible cross-talk
between the contact system (intrinsic pathway) and complement may exist at low pH
with subsequent complement activation. The current article reviews the published data
on the effect of pH on the contact system and complement activity, the nature of the pH
sensor molecules, and the clinical implications of these effects. Of particular interest is
chronic kidney disease (CKD) accompanied by metabolic acidosis, in which therapeutic
alkalinization of urine has been shown significantly to reduce tubular complement activa-
tion products, an effect, which may have important implications for slowing progression
of CKD.
Keywords: complement, coagulation, contact system, alternative pathway, lectin pathway, classical pathway, pH
Introduction – The Physiological and Clinical Importance of pH
Effects on Complement
It has been known for many years that complement is strongly activated by low pH, especially when
pH falls below about 7.1 (1–7). Owing to the tight regulation of arterial blood pH close to the normal
physiological value of 7.4 that occurs even under pathological conditions, complement and plasma
proteins in major blood vessels are unlikely to be exposed to such low pH. However, at sites of
infection or inflammation, a significant localized fall in pH can occur, reaching pH 6 or even lower
(8–10). Furthermore, other fluid compartments in mammals, notably the fluid within the lumen of
the renal tubule, routinely maintain pH values below 7.1 (Table 1).
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In healthy individuals, the lumen of the renal tubule is not
routinely exposed to plasma proteins (including complement pro-
teins). However, in chronic kidney disease (CKD), leakage of
such proteins commonly occurs, resulting in proteinuria. There
is now abundant evidence (18) that proteinuria is a major fac-
tor driving progression of CKD, and that the leakage of plasma
proteins into the tubular lumen triggers an array of patholog-
ical changes in proximal tubular epithelial cells (PTEC) (18–
20), including hyperplasia and epithelial–mesenchymal transition
(EMT), which culminate in end-stage tubulointerstitial fibrosis.
The complement system is widely recognized as a key mediator of
renal injury (21) and there is mounting evidence that activation
of plasma complement proteins leaking into the tubular lumen
during proteinuria, followed by strong activation of locally syn-
thesized complement (22) leads to progressive tubulointerstitial
damage. Significant amounts of complement activation products
are excreted in urine of patients with many forms of proteinuric
nephropathy (23) and this excretion of activation products is
blunted when metabolic acidosis in these patients is treated with
sodium bicarbonate (NaHCO3) (23), even though bicarbonate
has no long-term effect on proteinuria (23, 24). This implies
that, in addition to the well-documented glomerular effects of
complement (25), filtered complement, strongly augmented by
endogenously expressed tubular complement (22), is activated by
the low intratubular pH (Table 1). Thismay explain the important
clinical observation (24) that progression of CKD is significantly
slowed in response to therapy with oral alkali (sodium bicarbon-
ate), much of which is excreted into the tubular lumen thus raising
intraluminal pH.
While renal complement-activation during metabolic acidosis
has traditionally been ascribed to covalent activation of comple-
ment C3 by ammoniagenesis (26), more recent direct measure-
ments have failed to substantiate this (7), and direct activation
of complement by physiological low pH (4–7) is a more likely
explanation, possibly through activation of the alternative path-
way (AP) (7, 27) and through pH-sensitive cross-talk between the
coagulation (contact) and complement systems.
The current article reviews and compares the basic features
of the complement and coagulation systems, cross-talk between
these two systems, and the mechanisms whereby low pH may
activate complement; in particular, the possibility that low pH
is sensed initially by the contact system (intrinsic pathway)
and that complement is then activated through contact system-
complement cross-talk.
The Complement and the Coagulation
Systems
The complement and the coagulation systems are two closely
linked systems that serve a vital role in maintaining homeostasis.
Their activities rely on a delicate balance between activator and
inhibitor signals of sequential enzymatic reactions that include
activation of zymogens and assembly of new proteolytic com-
plexes. Complement is now thought to be involved in several
activities besides its role in fighting infections: these include tissue
regeneration (28), clearance of debris (29), and pathophysiology
of multiple diseases (30, 31). Likewise, the coagulation system
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plays a role in fighting infections (32) and is implicated in patho-
physiology of several diseases besides its role in the maintenance
of hemostasis. Furthermore, complex cross-talk between comple-
ment and the coagulation system has been described that will be
addressed in the current review, particularly with regard to medi-
ating the activation of complement by physiologically attainable
low pH.
The Complement System
Complement, as an integral part of the innate immune system has
amajor role in defense against invading pathogens. It achieves this
through threemain strategies; recruitment of immune cells to sites
of infection, labeling of the invading pathogens via opsonization
for uptake and destruction by phagocytes, and/or direct lysis
of susceptible pathogens. Besides bridging innate and adaptive
immunity, complement also bridges the immune and coagulation
systems. More than 35 proteins, including circulating zymogens,
and an array of fluid phase and membrane-bound regulators and
cell-bound receptors, participate in complement activities. Three
pathways have been recognized for complement activation; the
classical pathway (CP), the AP, and the more recently discovered
lectin pathway (LP) (33–35). The CP and LP are analogous, differ-
ing only in the initiator molecular complexes and the triggering
signals (36). Complement C1q in association with two molecules
of each of the serine proteases C1r and C1s makes the initia-
tor complex of the CP (37). The C1qrs complex is activated on
binding to antigen–antibody complex; however, it can also be
activated in an antigen–antibody independent manner by binding
to a number of molecules including C-reactive protein (CRP),
lipopolysaccharide (LPS), polyanions, viral proteins, pneumolysin
(38), and myelin. The LP-initiating complexes are made up of
carbohydrate recognition molecules of either mannose binding
lectin (MBL), ficolins or collectin-11 (Cl-11) associated with ser-
ine proteases, namely, MASP-1, MASP-2, and MASP-3 (39). LP
is initiated upon recognition of certain sugar or acetylated sugar
patterns decorating surfaces of invading microbes by the broad-
spectrum carbohydrate recognition molecules of the LP. Unlike
CP and LP, AP activation does not proceed via specific recogni-
tion molecules, but occurs instead through an imbalance between
activating and inactivating signals acting on a steady state tick over
process (40, 41). This kind of imbalance occurs on susceptible
surfaces that lack complement regulators or do not support the
binding of such regulators that normally occur on host cells. In
addition, AP acts as a loop for amplification of signals from the
other two pathways (42, 43).
Binding of recognition complexes from either CP or LP to
their target structures leads to conformational changes within the
molecules that result in activation of the attached serine proteases;
C1r/C1s and MASP-1/MASP-2, respectively. The activated serine
proteases C1s and MASP-2 cleave C4 into C4a and C4b. C4a is
released into the fluid phase, whereas C4b attaches to the target
surface. C2 binds to the attached C4b and is cleaved by C1s or
MASP-2 releasing C2b into the fluid phase, whereas C2a remains
attached to C4b. The resulting complex C4b2a represents the
C3-convertase of the CP/LP that then activates C3. The slow
and spontaneous hydrolysis of C3 into C3(H2O) is considered
to provide the flux that maintains the AP activity. The resulting
C3(H2O) is able to bind to factor B (FB), rendering it susceptible
to cleavage by factor D (FD). This produces a limited amount
of the fluid phase AP C3-convertase [C3(H2O)Bb] that is able
to cleave C3 into C3a and C3b. In absence of surface regulators
or surfaces that do not support factor H (FH) binding (the main
negative regulator of AP), the C3b formed binds to target surfaces
and assembles with FB (in presence of FD) the surface AP C3-
convertase (C3bBb) (44) that is stabilized by properdin (45, 46).
All of the three complement activation pathways converge
in the proteolytic cleavage of C3, where C3 is cleaved into the
anaphylatoxin C3a, and the opsonin C3b that binds covalently
to the target surface. Binding of several molecules of the C3b to
C3-convertases (either from CP/LP or AP) results in the assembly
of C5-convertase that cleaves C5 into the powerful anaphylatoxin
C5a and the opsonin C5b. Opsonization of target cells with C5b
allows, in certain cases, the assembly of terminal complement
components C6, 7, 8, and 9 into the membrane attack complex
(MAC) that inserts into target membranes forming channels that
disruptmembrane function and lead to lysis of target cells (47, 48).
The Coagulation System
The intrinsic pathway of coagulation was first described by two
independent laboratories that proposed the waterfall model (49)
and the cascade model (50) of coagulation (Figure 1). Following
the discovery of tissue factor (TF) (also called factor III orCD142),
the waterfall/cascade models were refined to include the extrinsic
pathway. However, these models could not fully explain in vivo
hemostasis or the normal bleeding tendency in patients lacking
some of the early components of the intrinsic pathway [the contact
system components: FXII, prekallikrein (PK) and highmolecular-
weight kininogen (HMWK)]. In addition, it was unclear why
patients with functional deficiency of the intrinsic pathway FVIII
(hemophilia A) or FIX (hemophilia B) have severe bleeding dys-
function despite the presence of the extrinsic pathway activity.
In 1990s, the emergence of the cell-based model of coagulation
provided plausible answers to these anomalies (51, 52).
The Extrinsic Pathway
Blood clotting through the extrinsic pathway of coagulation
depends on the interaction between the circulating active form
of FVII (FVIIa) and the membrane-bound TF to form a serine
protease complex that activates FX into FXa (see Figure 1). FVII
is the only coagulation factor found in circulation in active (1%)
and inactive forms (53). The mechanism of FVII activation is still
unconfirmed; however, autoactivation is suggested to provide the
circulating FVIIa (54, 55). Other factors including FXIIa, FXa,
FIXa, thrombin, plasmin, and FVII-activating protease also show
the ability to activate FVII (56). Under physiological conditions,
TF is not accessible to blood components, and only becomes
accessible following injury to the endothelial cells lining the blood
vessels. TF is expressed in a number of cells, including adventitial
cells in the layers surrounding blood vessels. It has been reported
that TF is also expressed in a number of activated cells (or cell-
derived particles) in the blood, including monocytes, monocyte-
derived microparticles, neutrophils, eosinophils, and platelets
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FIGURE 1 | Diagram showing an overview of coagulation pathways.
(57–62). However, intravascular TF exists in an encrypted form
that cannot interact with FVIIa unless decrypted, possibly through
the enzymatic activity of protein disulfide isomerase (63–65).
Intravascular TF is thought to be involved in thrombosis (a patho-
logical form of coagulation) rather than normal hemostasis (57,
59, 66). The extrinsic pathway is believed to be the only physio-
logical trigger of coagulation in vivo that is activated immediately
upon blood vessel injury (67).
The Intrinsic Pathway and the Contact
System
The intrinsic pathway of coagulation is triggered upon the activa-
tion of the first component of the contact system “FXII” into FXIIa
by an activator surface that is usually a negatively charged surface
(68). The in vivo physiological activators of FXII are still unclear;
however, platelet-derived polyphosphate (54, 69, 70) and mast
cell heparin (71) are suggested to be contributory physiological
activators of the contact system. Other known activators of FXII
include extracellular RNA (72), DNA (73), collagen, Kaolin (74),
dextran sulfate (75, 76), oversulfated chondroitin sulfate (77),
glass, and plastic. FXIIa activates the second component of the
contact system–PK into kallikrein. PK circulateswith the cofactor
HMWK (the third contact system component). The resulting
kallikrein promotes the activation of additional FXII molecules
via a positive feedback loop (Figure 1). These first two steps in
contact system activation do not require the presence of calcium
ions. The resulting FXIIa in the presence of calcium ions, phos-
pholipids (phosphatidylserine provided by activated platelet sur-
faces), and the cofactor HMWK activates FXI into FXIa (78). FXIa
then activates FIX into FIXa in the presence of calcium ions and
phospholipids. FIXa forms (with the cofactor FVIIIa, in presence
of calcium ions and phospholipids) a serine protease “Tenase” that
activates FX into FXa. The resulting FXa either from the extrinsic
or the intrinsic pathway forms, with the cofactor “FVa,” a serine
protease called “prothrombinase” that activates prothrombin (FII)
into thrombin (the common pathway). The resulting thrombin
then acts on fibrinogen, releasing fibrin monomer that is cross-
linked in the presence of FXIIIa to form a stable fibrin poly-
mer clot. Besides the procoagulant activity, kallikrein can cleave
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HMWK to release the proinflammatory peptide “bradykinin”
(kallikrein-kinin pathway) that acts on multiple target cells with
the production of inflammatory mediators that include prostacy-
clin, prostaglandins, leukotrienes, endothelial-derived hyperpo-
larizing factor, and nitric oxide (79). By generation of bradykinin,
the contact system plays an additional role, promoting other
immune defense mechanisms during infection [for review, see
Ref. (80)].
Growing evidence suggests that the contact system has sur-
prisingly little impact on physiological hemostasis. Deficiency of
FXII in humans and other animal species is not associated with
deficient hemostasis. Moreover, non-mammalian vertebrates and
cetaceans do not have FXII (81). On the other hand, it is strongly
suspected that the contact system is associated with thrombosis
(82). Deficiency of the contact system is protective against devel-
opment of thrombosis and stroke (32, 83, 84). It is now believed
that the mechanisms of physiological hemostasis are different
from those of thrombosis (82) and thrombosis can be triggered
via the activation of FXII by platelets and erythrocyte-derived
microparticles (85). Current therapeutic strategies in thrombosis
focus on targeting the contact system, hence affording protection
from thrombosis or embolism without interfering with the hemo-
static capacity. In view of the apparent links between the contact
system and the activation of complement at low pH (discussed
below), the contact systemmight also be a suitable therapeutic tar-
get in blocking the detrimental effects of complement activation
under acidic conditions.
The Cell-Based Model of Coagulation
A more complete understanding of in vivo coagulation requires
the cell-based model of coagulation, in which cell surfaces play a
role distinct fromproviding the phospholipids required for assem-
bly of protease complexes via platelet surfaces. The initiation step
is believed to occur continuously in the extravascular tissue fluids
and lymph, into which coagulation factors such as FVII, FIX, FX,
prothrombin, and other lowmolecular-weight coagulation factors
can diffuse from blood (51). In this step, FVIIa binds to TF on TF-
bearing cells to form TF/FVIIa complex that activates FX to FXa.
The resulting FXa activates prothrombin to thrombin before being
rapidly inactivated by tissue factor pathway inhibitor (TFPI) and
antithrombin III (86, 87). At the same time, TF/FVIIa complex
activates FIX into IXa (88) that is required in further steps. Thus,
this initiation step provides a continuous supply of trace amounts
of extravascular thrombin that is required for further steps in the
event of blood vessel injury. If such injury occurs, the following
amplification and propagation steps will be triggered, involving
blood coagulation factors and platelets that cannot normally dif-
fuse from blood vessels into surrounding tissues. This occurs
when these come into contact with the thrombin generated from
the initiation phase (as described above), and the TF-bearing cells
and subendothelial collagen.
Subsequently, platelets will be activated at the injury site by
thrombin and collagen (89), releasing FV that becomes activated
by thrombin on the platelet surface (see Figure 1). At the same
time, thrombin will release FVIII from von Willebrand factor
(vWF)-FVIII complex and activate it to FVIIIa. During this
amplification step, the activated platelets are covered with the
cofactors FVIIIa and FVa. The amount of thrombin generated at
this stage is not sufficient to drive clot formation; however, it is
very important for the amplification of the procoagulant signal.
In the subsequent propagation step, FIXa produced either from
TF/FVIIa complex or from FXIa generated via thrombin action
on FXI [in the presence of polyphosphate (90)] will bind to FVIIIa
on platelets in the presence of calcium ions to form tenase that is
50 times more efficient than TF/FVIIa complex in FX activation
(87), thus releasing large amounts of FXa. This FXa assembles with
FVa and calcium to form prothrombinase on the activated platelet
surface that will generate copious amounts of thrombin, which
drive fibrin clot formation. Accordingly, TF/FVIIa appears to be
the primary physiological trigger of in vivo coagulation (67) and
contact system components (FXII, PK, and HMWK) do not seem
to have a major role.
Cross-Talk between Complement and
Coagulation Systems
The complement and coagulation systems share a number of com-
mon features. Activation of both systems leads to conversion of
zymogens and assembly of proteolytic complexes that are mostly
serine proteases of high-substrate specificity. Interactions between
complement and coagulation systems have been described in a
number of publications. For example, some complement regula-
tors such as complement C1 inhibitor are involved in regulation
of the contact system (91), and serine proteases from either of
the two systems may act on substrates from the other system.
For this reason, severe trauma and acute blood loss are not only
associated with disseminated intravascular coagulopathy (DIC)
but also with massive complement activation. This generates the
potent anaphylatoxins C3a and C5a, and these may in their turn
intensify coagulation (92–94). Activated platelets, which are crit-
ical participants in coagulation, can also activate both the CP
(95) and the AP (96, 97); however, the physiological impact of
this activation is still unknown, although complement activation
products are known to activate platelets (97), which may lead to a
positive feedback loop.
Thrombin generated from the coagulation system can activate
complement C3 and C5 independent of the established comple-
ment activation pathways (98). Furthermore, C3 and C5 acti-
vation can proceed independent of each other (98). Similarly,
Amara et al. (92, 99) reported the cleavage of C3 and C5, with
the generation of C3a and C5a, respectively, by the coagulation
factors FIXa, FXa, FXIa, and plasmin (100) independent of the
known complement activation pathways. Thrombin and plasmin
have been suggested to activate complement during liver regen-
eration in the absence of C4 and AP activity (28). In addition,
FXIIa has been shown to activate the CP of complement via
activation of C1qrs complex (101). Surprisingly, fluid phase acti-
vation of FXII by oversulfated chondroitin sulfate activated not
only the contact (Kallikrein-Kinin) system but also C3 and C5
in the presence of EDTA (77). EDTA is a well-known inhibitor
of complement via all of the known activation pathways by
sequestering the divalent cations (Ca2+ and Mg2+) necessary for
complement activation. Thus, C3 and C5 activation can proceed
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by a mechanism that is independent of the known C3- and C5-
convertases. Depletion of FXII from plasma abolished this acti-
vation without affecting the normal complement activity; and
reconstitution of depleted plasma with purified FXII restored
complement activation (77).
However, not all such effects involve FXII: the use of apro-
tonin – a protease inhibitor of kallikrein and plasmin (but not of
FXII) – inhibited C5 activation by oversulfated chondroitin sulfate
(77). Furthermore, plasminogen-depleted plasma also failed to
induce C5a production by oversulfated chondroitin sulfate (77).
Thus, it seems that the contact system activity – not exclusively
the individual activities of FXIIa or kallikrein – may drive com-
plement C3 and C5 activation through generation of plasmin that
has previously been reported to cleave C3 and C5 (77, 92, 100).
Wiggins et al. (102) showed that purified rabbit kallikrein was
able to generate from rabbit C5 an activity that was chemotac-
tic for rabbit neutrophils, suggesting that Kallikrein may cleave
C5. Besides that, kallikrein was shown to play a role similar
to factor D in cleaving C3bB, generating the AP C3-convertase
C3bBb. However, this activity required the presence of divalent
cations (103).
Conversely, complement components have been shown to
influence coagulation activity in multiple ways. The key enzyme
of LP activation (MASP-2) is able to generate thrombin through
direct cleavage of prothrombin (104). Likewise, the terminal com-
plement component complex C5b–9 has similar activity toward
prothrombin even in absence of FV (105). Moreover, both the
sublytic MAC and the cytolytically inactive terminal complement
complex exhibit procoagulant activity mediated via the induction
of TF expression by endothelial cells (106). The anaphylatoxin
C5a promotes procoagulant activity by several actions on cells.
C5a induces the upregulation of TF expression by endothelial
cells (107) and by neutrophils (108). In addition, C5a induces the
switch of mast cell and basophil activities from profibrinolytic to
prothrombotic through the upregulation of plasminogen activator
inhibitor-1 (PAI-1) (109). Interaction between the twomembrane
receptors TF and complement C5a receptor (C5a R) further
suggests a cross-talk between the two systems (108). Accord-
ingly, there is considerable evidence for two-way communica-
tion between complement and coagulation system components,
influencing the activities of both systems.
Complement and Contact System
Activities at Acidic pH
Several in vitro studies have demonstrated potent activation of
complement activity, at acidic pH values, some of which are in the
physiologically relevant range shown in Table 1 (1–7). However,
care is needed in interpreting these effects for two reasons: first
because in vivo the low pH may have multiple sites of action (as
in the case of renal tubules or inflammatory foci); and second
because not all such effects observed in vitro may be directly
physiologically relevant because they require extremely low pH
or non-physiological temperature. For example, Hammer et al.
(1) reported that acidification of serum or C5 and C6 to pH
6.4 at 0°C followed by neutralization was associated with com-
plement activation that led to lysis of non-sensitized red blood
cells in presence of terminal complement components C7, C8,
and C9. They attributed the observed activity to the formation
of a complex between C5 and C6 similar in activity to that of
C5b6 generated via the AP or the CP. This complex was thought
to be formed as a result of C6-mediated cleavage of C5 α-chain
aided by low pH, which changed the tertiary structure of either
or both of C5 and C6. However, the physiological significance
of this complex is uncertain, as it was unstable at physiological
temperature (37°C).
Low pH may also exert multiple effects through the AP. AP
hemolytic activity on erythrocytes from paroxysmal nocturnal
haemglobinuria (PNH) patients (110, 111) and rabbit erythro-
cytes was enhanced at pH 6.4 compared to pH 7.4 (2), which
forms the basis of Ham’s test used in diagnosis of PNH (110).
They explained the enhancement of activity through the increased
formation of the two C3-convertases; C3(H2O)Bb and C3bBb, in
addition to the enhanced binding of FB and C5 to C3b deposited
on erythrocytes at pH 6.4. At the same time, the inhibitory effect
of CR1 and factor I (FI) was also diminished at this pH. Similarly,
Peake et al. (7) suggested thatmaximal complement deposition on
cultured PTEC occurred via the AP at acidic pH.
Complement activation undermildly acidic conditions has also
been attributed to human CRP via the CP (3). CRP is known
to trigger CP activation upon interaction with phosphocholine-
containing or polycationic agents. However, even in absence of
these agents, CRP has been reported to activate complement, with
optimal activity at pH 6.3. Furthermore, Hammond et al. (112)
showed that CRP was able to interact with FH, which may be
a way of partially regulating the enhanced complement activity
mediated by CRP at low pH. However, it should be noted that this
interaction of CRP with FH required more acidic pH (5.2–4.6).
Contact System-Complement Cross-Talk
as a Mediator of the Effect of Low pH on
Complement
Apart from the evidence cited above, relatively little is known
of direct effects of mildly acidic pH on complement proteins or
complement regulatory proteins. An alternative explanation of
the activation of complement by low pH is that pH is initially
sensed by component(s) of the contact system and this then
leads indirectly to complement activation through complement-
coagulation cross-talk. In the study involving CRP cited above
(3), complement activation occurred in glass tubes, but not
in polypropylene tubes. Addition of Kaolin to polypropylene
tubes restored complement activation, suggesting a requirement
for the presence of negatively charged surfaces to support the
pH-dependent CRP-mediated complement activation (3). These
authors attributed these effects of low pH to the conformational
changes that CRP underwent at this pH. However, a possible
alternative explanation is that the contact system is involved in
this CRP-mediated complement activation at mild acidic pH (3),
as activation occurred only in the presence of negatively charged
surfaces, conditions that activate the contact system as well.
Further evidence in support of a role for the contact system
in mediating the activation of complement by low pH (through
complement-coagulation cross-talk) comes from the observation
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that low pH results in accumulation of FXIIa as well as
complement activation products. Generation of complement acti-
vation products C3a and C5a was observed by Emeis et al. (4)
upon acidification of blood with either HCl or lactic acid. This
complement activation was attributed to the effect of acidic pH
itself, not to the lactate anion, as addition of lactate at control
(non-acidic) pH had no such effect. Likewise, respiratory acidosis
of blood was also associated with increase in C3a and C5a lev-
els. Lactate acidosis could activate not only C3 and C5 but also
more distal steps in the complement system, with the formation
of the soluble terminal complement complex (sC5b–9) either
in adults or neonates (113). In addition, Sonntag et al. (5, 6)
showed that acidification of blood and plasma with lactic acid was
associated with dose-dependent increase in complement C5a and
contact system FXIIa generation, even in the absence of cellular
components. Similarly, Renaux et al. (114) and Thomas et al.
(115) reported increased contact system activity with increased
kallikrein activity and bradykinin formation during hemodialysis
upon lowering the pH of diluted plasma from pH 7.4 to 7.1.
In addition to the in vitro studies, parallel activation of com-
plement and the contact system has also been observed in vivo in
conditions associated with tissue acidosis, for example, in cases of
myocardial infarction, shock, and perinatal asphyxia, where the
anaphylatoxins C3a and C5a, and FXIIa levels were elevated (5, 6,
116, 117).
The molecular basis of this apparent strong relation between
complement activation and contact system activation under
mildly acidic pH conditions, where the contact system is probably
the driving force for the complement activation, is still unclear.
The pH sensor molecule(s) involved are unknown. A highly pH-
sensitive plasma protein is the histidine proline-rich glycopro-
tein [HPRG – reviewed in Ref. (118)] in which much of the
pH sensitivity is attributable to the “histidine rich” region of
the molecule. Even though HPRG is known to associate with
complement proteins (118, 119), no direct acid-dependent acti-
vation of complement by this molecule has ever been demon-
strated. However, an interesting potential link with the contact
system arises from the observation that HPRG and HMWK show
about 50% sequence identity in their “histidine rich” region (118),
indicating a possible direct pH-sensing role by HMWK.
In view of the apparent links between acid-dependent comple-
ment activation and the progression of CKD that were reviewed
at the start of this article, the molecular basis of this effect of low
pH, and the involvement of possible pH sensing in the contact
system, merits further investigation; particularly as conventional
therapy for correction of low pH by administering oral sodium
bicarbonate toCKDpatientsmay carrywith it cardiovascular risks
associated with sodium loading. Selective inhibition of the con-
tact system (which may be possible without impairing hemosta-
sis) might be a suitable alternative therapeutic target. However,
before this possibility is pursued, two important points about the
activation of complement at low pH remain to be clarified:
First, if the complement activation ultimately arises from
complement-coagulation system cross-talk, with the cleavage of
C3 and C5, by FIXa, FXa, FXIa, and plasmin (100), it needs to
be confirmed that these proteases are still active at the relevant
low pH. If this is important in the renal tubular lumen during
proteinuria, it also needs to be shown that the failure of glomerular
permselectivity during proteinuria is sufficient to allow the rel-
evant contact system components (and not just complement) to
leak into the acidic renal tubular lumen.
Second, it needs to be confirmed that the effect of elevated pH
in vitro, or the therapeutic effect of alkalinizing the tubular lumen
with bicarbonate therapy in vivo (24) arises from inhibiting the
contact system, rather than through blocking the other proposed
effects of low pH on complement, such as acid-induced amplifi-
cation of spontaneous AP activity or enhanced binding of FB and
C5 to C3b (2).
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